Next Article in Journal
The Effect of Tau and Taxol on Polymerization of MCF7 Microtubules In Vitro
Next Article in Special Issue
Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover
Previous Article in Journal
Identification of a Novel Oncogenic Fusion Gene SPON1-TRIM29 in Clinical Ovarian Cancer That Promotes Cell and Tumor Growth and Enhances Chemoresistance in A2780 Cells
Previous Article in Special Issue
Roles of Non-Canonical Wnt Signalling Pathways in Bone Biology

Irisin and Secondary Osteoporosis in Humans

Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy
Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, 70124 Bari, Italy
Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, 16132 Genoa, Italy
Department of Clinical and Experimental Medicine, University of Foggia, 71100 Foggia, Italy
Authors to whom correspondence should be addressed.
Academic Editor: Alberto Falchetti
Int. J. Mol. Sci. 2022, 23(2), 690;
Received: 30 November 2021 / Revised: 31 December 2021 / Accepted: 5 January 2022 / Published: 8 January 2022
(This article belongs to the Special Issue Osteoporosis)
Irisin is a peptide secreted by skeletal muscle following exercise that plays an important role in bone metabolism. Numerous experiments in vitro and in mouse models have shown that the administration of recombinant irisin promotes osteogenesis, protects osteocytes from dexamethasone-induced apoptosis, prevents disuse-induced loss of bone and muscle mass, and accelerates fracture healing. Although some aspects still need to be elucidated, such as the dose- and frequency-dependent effects of irisin in cell cultures and mouse models, ample clinical evidence is emerging to support its physiological relevance on bone in humans. A reduction in serum irisin levels, associated with an increased risk of osteoporosis and bone fractures, was observed in postmenopausal women and in both men and women during aging, Recently, cohort studies of subjects with secondary osteoporosis showed that these patients have lower circulating levels of irisin, suggesting that this myokine could be a novel marker to monitor bone quality in this disease. Although there are still few studies, this review discusses the emerging data that are highlighting the involvement of irisin in some diseases that cause secondary osteoporosis. View Full-Text
Keywords: irisin; osteoporosis; hyperparathyroidism; Prader–Willi syndrome; growth hormone; Cushing’s disease; inflammatory bowel disease irisin; osteoporosis; hyperparathyroidism; Prader–Willi syndrome; growth hormone; Cushing’s disease; inflammatory bowel disease
Show Figures

Figure 1

MDPI and ACS Style

Zerlotin, R.; Oranger, A.; Pignataro, P.; Dicarlo, M.; Maselli, F.; Mori, G.; Colucci, S.C.; Grano, M.; Colaianni, G. Irisin and Secondary Osteoporosis in Humans. Int. J. Mol. Sci. 2022, 23, 690.

AMA Style

Zerlotin R, Oranger A, Pignataro P, Dicarlo M, Maselli F, Mori G, Colucci SC, Grano M, Colaianni G. Irisin and Secondary Osteoporosis in Humans. International Journal of Molecular Sciences. 2022; 23(2):690.

Chicago/Turabian Style

Zerlotin, Roberta, Angela Oranger, Patrizia Pignataro, Manuela Dicarlo, Filippo Maselli, Giorgio Mori, Silvia Concetta Colucci, Maria Grano, and Graziana Colaianni. 2022. "Irisin and Secondary Osteoporosis in Humans" International Journal of Molecular Sciences 23, no. 2: 690.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop